血脂水平对多发性硬化的影响相关性研究进展
摘要
<正>多发性硬化(MS)是一种自身免疫性疾病,以中枢神经系统白质炎性脱髓鞘病变为主,确切的病因及发病机制目前尚不明确。据相关研究显示异常血脂水平与MS病程进展及残疾严重程度相关,本文就MS与血脂关系研究进展综述如下。1 MS与血脂的相关性MS的特征性病理改变为中枢神经系统(CNS)白质内多发性脱髓鞘斑块形成,最常累及的部位为脑室周围、近皮质、视神经、脊髓、脑干、小脑,临床特点为病灶的空间和时间多发性,确切病因不明,可能与病毒感染、自身免疫反应或遗传等多种因素
引文
[1]Ratelade J,Zhang H,Saadoun S,et al.Neuromyelitis optica IgGand natural killer cells produce NMO lesions in mice without myelin loss[J].Acta Neuropathol,2012,123(6):861-872.
[2]Gold ES,Diercks AH,Podolsky I,et al.25-Hydroxycholesterol acts as an amplifier of inflammatory signaling[J].Proc Natl Acad Sci USA,2014,111(29):10666-10671.
[3]Fellows K,Uher T,Browne RW,et al..Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients[J].J Lipid Res,2015,56(10):2010.
[4]Vitali C,Wellington CL,Calabresi L.HDL and cholesterol handling in the brain[J].Cardiovasc Res,2014,103(3):405-13.
[5]Cha E,Lee KM,Park KD,et al.Hydroxycholesterol levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with picolinic derivatization:increased levels and association with disability during Acute Attack.[J].PLo S One,2016,11(12):e0167819.
[6]Olkkonen VM,Béaslas Olivier,Eija N.Oxysterols and Their cellular effectors[J].Biomolecules,2012,2(1):76-103.
[7]Lennon VA.IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel[J].J Exp Med,2005,202(4):473-477.
[8]Ratelade J,Zhang H,Saadoun S,et al.Neuromyelitis optica IgGand natural killer cells produce NMO lesions in mice without myelin loss[J].Acta Neuropathol,2012,123(6):861-872.
[9]Mandoj C,Renna R,Plantone D,et al.Anti-annexin antibodies,cholesterol levels and disability in multiple sclerosis[J].Neurosci Lett,2015,606:156-160.
[10]Giubilei F,Antonini G,Di LS,et al.Blood cholesterol and MRIactivity in first clinical episode suggestive of multiple sclerosis[J].Acta Neurol Scand,2002,106(2):109-112.
[11]Morra LF,Donovick PJ.Clinical presentation and differential diagnosis of dementia with Lewy bodies:a review[J].Int JGeriatric Psychiat,2014,29(6):569-576.
[12]Noseworthy JH,Lucchinetti C,Rodriguez M,et al.Multiple sclerosis[J].N Engl J Med,2000,343(13):938-952.
[13]Chataway J,Schuerer N,Alsanousi A.Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis(MS-STAT):a randomised,placebo-controlled,phase 2 trial[J].Lancet,2014,383(9936):2213-2221.
[14]梅俊,徐风芹.高密度脂蛋白逆转运胆固醇的分子生物学基础[J].中国动脉硬化杂志,2019,27(3):267-272.
[15]Mahley RW.Apolipoprotein E:cholesterol transport protein with expanding role in cell biology[J].Science,1988,240(4852):622.
[16]Gaillard O,Gervais A,Meillet D,et al.Apolipoprotein E and multiple sclerosis:a biochemical and genetic investigation[J].J Neurol Sci,1998,158(2):180-186.
[17]Rafiei M,Yeganeh MZ,Sheikholeslami S,et al.Apolipoprotein E polymorphisms status in Iranian patients with multiple sclerosis[J].J Neurol Sci,2012,320(1-2):22-25.
[18]Pinholt M,Frederiksen JL,Christiansen M.The association between apolipoprotein E and multiple sclerosis[J].Eur JNeurol,2010,13(6):573-580.
[19]Yin YW,Zhang YD,Wang JZ,et al.Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis:a meta-analysis of 6977 subjects[J].Gene,2012,511(1):12-17.
[20]Meyers L,Groover CJ,Douglas J,et al.A role for apolipoprotein A-I in the pathogenesis of multiple sclerosis[J].JNeuroimmunol,2014,277(1-2):176-185.
[21]Jacobson TA.Opening a new lipid“Apo-thecary”:incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk[J].Mayo Clinic Proceedings,2011,86(8):762-780.
[2]Gold ES,Diercks AH,Podolsky I,et al.25-Hydroxycholesterol acts as an amplifier of inflammatory signaling[J].Proc Natl Acad Sci USA,2014,111(29):10666-10671.
[3]Fellows K,Uher T,Browne RW,et al..Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients[J].J Lipid Res,2015,56(10):2010.
[4]Vitali C,Wellington CL,Calabresi L.HDL and cholesterol handling in the brain[J].Cardiovasc Res,2014,103(3):405-13.
[5]Cha E,Lee KM,Park KD,et al.Hydroxycholesterol levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with picolinic derivatization:increased levels and association with disability during Acute Attack.[J].PLo S One,2016,11(12):e0167819.
[6]Olkkonen VM,Béaslas Olivier,Eija N.Oxysterols and Their cellular effectors[J].Biomolecules,2012,2(1):76-103.
[7]Lennon VA.IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel[J].J Exp Med,2005,202(4):473-477.
[8]Ratelade J,Zhang H,Saadoun S,et al.Neuromyelitis optica IgGand natural killer cells produce NMO lesions in mice without myelin loss[J].Acta Neuropathol,2012,123(6):861-872.
[9]Mandoj C,Renna R,Plantone D,et al.Anti-annexin antibodies,cholesterol levels and disability in multiple sclerosis[J].Neurosci Lett,2015,606:156-160.
[10]Giubilei F,Antonini G,Di LS,et al.Blood cholesterol and MRIactivity in first clinical episode suggestive of multiple sclerosis[J].Acta Neurol Scand,2002,106(2):109-112.
[11]Morra LF,Donovick PJ.Clinical presentation and differential diagnosis of dementia with Lewy bodies:a review[J].Int JGeriatric Psychiat,2014,29(6):569-576.
[12]Noseworthy JH,Lucchinetti C,Rodriguez M,et al.Multiple sclerosis[J].N Engl J Med,2000,343(13):938-952.
[13]Chataway J,Schuerer N,Alsanousi A.Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis(MS-STAT):a randomised,placebo-controlled,phase 2 trial[J].Lancet,2014,383(9936):2213-2221.
[14]梅俊,徐风芹.高密度脂蛋白逆转运胆固醇的分子生物学基础[J].中国动脉硬化杂志,2019,27(3):267-272.
[15]Mahley RW.Apolipoprotein E:cholesterol transport protein with expanding role in cell biology[J].Science,1988,240(4852):622.
[16]Gaillard O,Gervais A,Meillet D,et al.Apolipoprotein E and multiple sclerosis:a biochemical and genetic investigation[J].J Neurol Sci,1998,158(2):180-186.
[17]Rafiei M,Yeganeh MZ,Sheikholeslami S,et al.Apolipoprotein E polymorphisms status in Iranian patients with multiple sclerosis[J].J Neurol Sci,2012,320(1-2):22-25.
[18]Pinholt M,Frederiksen JL,Christiansen M.The association between apolipoprotein E and multiple sclerosis[J].Eur JNeurol,2010,13(6):573-580.
[19]Yin YW,Zhang YD,Wang JZ,et al.Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis:a meta-analysis of 6977 subjects[J].Gene,2012,511(1):12-17.
[20]Meyers L,Groover CJ,Douglas J,et al.A role for apolipoprotein A-I in the pathogenesis of multiple sclerosis[J].JNeuroimmunol,2014,277(1-2):176-185.
[21]Jacobson TA.Opening a new lipid“Apo-thecary”:incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk[J].Mayo Clinic Proceedings,2011,86(8):762-780.